NeuroOne Medical Technologies Corp (NASDAQ:NMTC) does about 124.60K shares in volume on a normal day but saw 1406793 shares change hands in the recent trading day. The company now has a market cap of 24.37M USD. Its current market price is $0.79, marking an increase of 4.53% compared to the previous close of $0.76. The 52 week high reached by this stock is $1.72 whilst the lowest price level in 52 weeks is $0.55.
NeuroOne Medical Technologies Corp (NMTC) has a 20-day trading average at $0.6917 and the current price is -54.02% off the 52-week high compared with 43.52% distance from its 52-week low. The 50-day simple moving average of the closing price is $0.8248 and its 200-day simple moving average is $0.9316. If we look at the stock’s price movements over the week, volatility stands at 18.89%, which decreases to 15.61% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 54.10 to suggest the stock is neutral.
The consensus objective for the share price is $2.00, suggesting that the stock has a potential upside of 60.5% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 29, 2022 when Craig Hallum downgraded the stock to “Hold” and issued a price target of between $6 and $2.
The current price level is 14.32%, -4.12%, and -15.11% away from its SMA20, SMA50, and SMA200 respectively, with the NMTC price moving above the 50-day SMA on current market day. NeuroOne Medical Technologies Corp (NMTC) stock is down -1.40% over the week and 11.22% over the past month. Its price is -49.95% year-to-date and -48.31% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 0 and 0 for whole year.
To reach the target analysts have set, the stock logically needs to grow 60.5 percent from here.
Outstanding shares total 27.85M with insiders holding 16.02% of the shares and institutional holders owning 19.43% of the company’s common stock. The company has a return on investment of -375.67% and return on equity of -349.13%. The beta has a value of 0.71. Price to book ratio is 7.31 and price to sales ratio is 6.22.
